{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:04:25Z","timestamp":1771261465077,"version":"3.50.1"},"reference-count":12,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1303,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[1998,6]]},"abstract":"<jats:p>We retrospectively investigated the feasibility and the toxicity of autologous stem cell transpantation (ASCT) in 21 cases of systemic amyloidosis (AL). The conditioning regimens consisted of high\u2010dose melphalan (HDM) alone (<jats:italic>n<\/jats:italic>\u2003=\u200318) or in combination with 12 Gy total body irradiation (<jats:italic>n<\/jats:italic>\u2003=\u20033). Toxic death rate was high: 9\/21 patients (43%) died within the first month following ASCT, and 10\/12 surviving patients achieved a response. With a median follow\u2010up of 14 months, the OS and the EFS rates at 4 years were 57.1% (\u00b110.8) and 29.9% (\u00b114.5) respectively for the whole group. The major prognostic factor for both response and survival was the number of clinical manifestations at the time of ASCT, of the following five criteria, i.e. creatinine clearance &lt;30\u2003ml\/min, nephrotic syndrome with urinary protein excretion &gt;\u20033000\u2003mg\/24\u2003h, congestive heart failure, neuropathy, or hepatomegaly associated with alkaline phosphatase level &gt;\u2003200\u2003IU\/l. For patients presenting with two or more clinical manifestations the 4\u2010year OS and EFS were both 11.1% compared with 91.7% and 46.3% respectively in patients with fewer than two clinical manifestations at the time of ACST. We conclude that ASCT is feasible in AL in a subset of patients with fewer than two clinical manifestations at the time of ASCT. Given the severe extra\u2010haematological toxicity, ASCT should not be considered in other cases.<\/jats:p>","DOI":"10.1046\/j.1365-2141.1998.00772.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:02:20Z","timestamp":1047362540000},"page":"766-769","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":191,"title":["Prognostic factors for survival and response after high\u2010dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients"],"prefix":"10.1111","volume":"101","author":[{"given":"Philippe","family":"Moreau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscille","family":"Bourquelot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Caillot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Attal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Hamidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Nedellec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augustin","family":"Ferrant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Audhuy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9gis","family":"Bataille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"No\u00ebl","family":"Milpied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Luc","family":"Harousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_5_2_2","unstructured":"Comenzo R.L. Falk R.H. Reisinger J. Dubrey S. Finn K. Sarnacki D. Berk J. Dember L. Bergethon P. LaValley M. Sanchorawala V. Vosburgh E. Skinner M.(1997) AL amyloidosis frequently remits after dose\u2010intensive melphalan with blood stem cell support: outcomes in 55 patients.VI International Workshop on Multiple Myeloma Boston abstract 6\u20105."},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709253371306"},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood.V77.2.257.257","article-title":"Response rates and survival in primary systemic amyloidosis","volume":"77","author":"Gertz M.A.","year":"1991","journal-title":"Blood"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.303194.x"},{"key":"e_1_2_5_7_2","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle R.A.","year":"1995","journal-title":"Seminars in Hematology"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704243361702"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/blood.V68.1.220.220","article-title":"Primary systemic amyloidosis: multivariant analysis for prognostic factors in 168 cases","volume":"68","author":"Kyle R.A.","year":"1986","journal-title":"Blood"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-7-199510010-00017"},{"key":"e_1_2_5_11_2","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood.V87.7.3063.bloodjournal8773063","article-title":"High\u2010dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement. (Letter)","volume":"87","author":"Moreau P.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)89487-9"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-7-199504010-00005"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.1998.00772.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.1998.00772.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1365-2141.1998.00772.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.1998.00772.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T06:57:36Z","timestamp":1694415456000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.1998.00772.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,6]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1998,6]]}},"alternative-id":["10.1046\/j.1365-2141.1998.00772.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.1998.00772.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,6]]},"assertion":[{"value":"2001-12-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}